Fulgent Genetics Stock News

Explore the exciting world of Fulgent Genetics (FLGT 2.11%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

While the stock price is unchanged since my buy rating a year ago, revenue growth is accelerating (FY25E: +14%) and gross margins are going up (FY25E: 40%, +200bps vs PY). Both precision diagnostics and anatomic pathology are positioned for sustainable double-digit revenue growth driven by innovation, increased insurance coverage, and geographic expansion. Meanwhile, Fulgent's Pharma segment co...

Fulgent (FLGT) Q2 Revenue Jumps 16%

Friday's stock market was generally a gloomy place, but apparently someone forgot to tell Fulgent Genetics (FLGT 7.80%). The company's shares were soaring in late-session action, with a very healthy rise of more than 8%.

Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q2 2025 Earnings Conference Call August 1, 2025 8:30 AM ET Company Participants Brandon Perthuis - Chief Commercial Officer Ming Hsieh - Chairman & CEO Paul Kim - Chief Financial Officer Conference Call Participants Andrew Harris Cooper - Raymond James & Associates, Inc., Research Division David Michael Westenberg - Piper Sandler & Co., Research Division Lu...

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its second quarter ended June 30, 2025. Second Quarter 2025 Results: Total Revenue of $81.8 million Core Revenue1 grew 16% year-over-ye...

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced it has received CE certification under the European Union (EU)'s In Vitro Diagnostic Regulation (EU) 2017/746 (IVDR) for its germline next-generation sequenc...

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2025 financial results before the market opens on Friday, August 1, 2025. Management will host a conference call for t...